Abstract
Background & Objective: Thioredoxin-interacting protein (TXNIP) also known as thioredoxin binding protein-2 is a ubiquitously expressed protein that interacts and negatively regulates expression and function of Thioredoxin (TXN). Over the last few years, TXNIP has attracted considerable attention due to its wide-ranging functions impacting several aspects of energy metabolism. TXNIP acts as an important regulator of glucose and lipid metabolism through pleiotropic actions including regulation of β-cell function, hepatic glucose production, peripheral glucose uptake, adipogenesis, and substrate utilization. Overexpression of TXNIP in animal models has been shown to induce apoptosis of pancreatic β-cells, reduce insulin sensitivity in peripheral tissues like skeletal muscle and adipose, and decrease energy expenditure. On the contrary, TXNIP deficient animals are protected from diet induced insulin resistance and type 2 diabetes.
Summary: Consequently, targeting TXNIP is thought to offer novel therapeutic opportunity and TXNIP inhibitors have the potential to become a powerful therapeutic tool for the treatment of diabetes mellitus. Here we summarize the current state of our understanding of TXNIP biology, highlight its role in metabolic regulation and raise critical questions that could help future research to exploit TXNIP as a therapeutic target.Keywords: Diabetes mellitus, thioredoxin system, thioredoxin-interacting protein, oxidative stress, insulin resistance, pancreatic β-cell dysfunction, metabolic homoeostasis.
Current Drug Targets
Title:TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Volume: 18 Issue: 9
Author(s): Naif Mohammad Alhawiti, Saeed Al Mahri, Mohammad Azhar Aziz, Shuja Shafi Malik and Sameer Mohammad*
Affiliation:
- Experimental Medicine, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard Health Affairs (NGHA), Riyadh,Saudi Arabia
Keywords: Diabetes mellitus, thioredoxin system, thioredoxin-interacting protein, oxidative stress, insulin resistance, pancreatic β-cell dysfunction, metabolic homoeostasis.
Abstract: Background & Objective: Thioredoxin-interacting protein (TXNIP) also known as thioredoxin binding protein-2 is a ubiquitously expressed protein that interacts and negatively regulates expression and function of Thioredoxin (TXN). Over the last few years, TXNIP has attracted considerable attention due to its wide-ranging functions impacting several aspects of energy metabolism. TXNIP acts as an important regulator of glucose and lipid metabolism through pleiotropic actions including regulation of β-cell function, hepatic glucose production, peripheral glucose uptake, adipogenesis, and substrate utilization. Overexpression of TXNIP in animal models has been shown to induce apoptosis of pancreatic β-cells, reduce insulin sensitivity in peripheral tissues like skeletal muscle and adipose, and decrease energy expenditure. On the contrary, TXNIP deficient animals are protected from diet induced insulin resistance and type 2 diabetes.
Summary: Consequently, targeting TXNIP is thought to offer novel therapeutic opportunity and TXNIP inhibitors have the potential to become a powerful therapeutic tool for the treatment of diabetes mellitus. Here we summarize the current state of our understanding of TXNIP biology, highlight its role in metabolic regulation and raise critical questions that could help future research to exploit TXNIP as a therapeutic target.Export Options
About this article
Cite this article as:
Alhawiti Mohammad Naif, Al Mahri Saeed, Aziz Azhar Mohammad, Malik Shafi Shuja and Mohammad Sameer*, TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook, Current Drug Targets 2017; 18 (9) . https://dx.doi.org/10.2174/1389450118666170130145514
DOI https://dx.doi.org/10.2174/1389450118666170130145514 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Glucose Intolerance and Diabetes Mellitus in Endocrine Disorders – Two Case Reports and a Review
Current Diabetes Reviews Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Utility of the Electrocardiogram in Drug Overdose and Poisoning: Theoretical Considerations and Clinical Implications
Current Cardiology Reviews Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Investigation on the Interaction Between Anthracyclines and DNA in the Presence of Quercetin by Resonance Light Scattering Technique and Its Analytical Application
Current Analytical Chemistry Genetics of Cardiomyopathies: Novel Perspectives with Next Generation Sequencing
Current Pharmaceutical Design Microvascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Pediatric Takayasu Arteritis: A Review of the Literature
Current Pediatric Reviews The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Effects of Ganoderma Lucidum on Contractile Dysfunction of the Rabbit Urinary Bladder using an In-Vitro Model of Ischemia/Reperfusion
The Natural Products Journal Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases
Current Pharmaceutical Design The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry